Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology (IKNA)
NASDAQ:IKNA
IKNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $1.94
Previous CloseN/A
Volume99.58K
Average Volume (3M)82.14K
Market Cap
$48.31M
Enterprise Value-$46.15M
Total Cash (Recent Filing)$39.39M
Total Debt (Recent Filing)$7.52M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
May 08, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding40,258,410
10 Day Avg. Volume62,666
30 Day Avg. Volume82,136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.27
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.85
Forecast
1Y Price Target
$4.00Price Target Upside253.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Ikena Oncology News
PremiumCompany Announcements
Ikena Oncology: Investor Caution as Dividend Payments Remain Unlikely
PremiumCompany Announcements
Ikena Oncology and Inmagene Announce Merger and Fundraising
PremiumCompany Announcements
Ikena Oncology Reports Strategic Realignment and Financial Performance
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentIK-595 is a novel, potentially best-in-class dual MEK-RAF complex inhibitor, representing a highly advanced approach to overcoming MAPK pathway-related drug resistance.
Merger BenefitsThe merger with Inmagene Biopharmaceuticals is expected to provide the combined company with an estimated $175 million in cash to support development of the anti-OX40 antibody, IMG-007.
Product PotentialThere is a blockbuster opportunity for IMG-007 in atopic dermatitis and longer-term potential in additional inflammatory and immunological indications.
Bears Say
Stock Price PressureThe removal of Ikena’s IK-930 (TEADi) has contributed to the stock’s current valuation near its 52-week low.
Stock ValuationFollowing the merger, current Ikena shareholders will own approximately 34.8% of the combined company, suggesting a combined company value of less than $300 million and enterprise value of below $120 million.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IKNA FAQ
What was Ikena Oncology’s price range in the past 12 months?
Ikena Oncology lowest stock price was $1.09 and its highest was $1.94 in the past 12 months.
What is Ikena Oncology’s market cap?
Ikena Oncology’s market cap is $48.31M.
When is Ikena Oncology’s upcoming earnings report date?
Ikena Oncology’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Ikena Oncology’s earnings last quarter?
Ikena Oncology released its earnings results on Mar 18, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.249 by $0.049.
Is Ikena Oncology overvalued?
According to Wall Street analysts Ikena Oncology’s price is currently Undervalued.
Does Ikena Oncology pay dividends?
Ikena Oncology does not currently pay dividends.
What is Ikena Oncology’s EPS estimate?
Ikena Oncology’s EPS estimate is -0.2.
How many shares outstanding does Ikena Oncology have?
Ikena Oncology has 40,258,410 shares outstanding.
What happened to Ikena Oncology’s price movement after its last earnings report?
Ikena Oncology reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.249. Following the earnings report the stock price went down -2.29%.
Which hedge fund is a major shareholder of Ikena Oncology?
Currently, no hedge funds are holding shares in IKNA
---
Ikena Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (253.98% Upside)
$4.00 (253.98% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.91%
12-Months-Change
Fundamentals
Return on Equity
-33.30%
Trailing 12-Months
Asset Growth
-26.33%
Trailing 12-Months
Company Description
Ikena Oncology
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
---
IKNA Stock 12 Month Forecast
Average Price Target
$4.00
▲(253.98% Upside)
Technical Analysis
Fate Therapeutics
―
Scholar Rock Holding
―
Precision BioSciences
―
IGM Biosciences
―
Thryv Holdings
―
Best Analysts Covering IKNA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-26.35%
reiterated a buy rating 5 months ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -26.35% per trade.
---